Expression and significance of miR-338 in hepatocellular carcinoma tissue samples

doi:10.3877/cma.j.issn.1674-0793.2011.06.003

Abstract

Abstract:

Objective

To detect the profile of 114 microRNA (miRNA) expression in hepatocellular carcinoma and investigate the relationship of miR-338 expression with clinicopathological parameters.

Methods

A bead-based miRNA expression profiling method was performed on 20 pairs of surgically removed HCC and adjacent non-tumorous tissue (NT). Special miR-338 downregulations and miR-338 associated with clinical characteristics was validated in an extended samples set of 36 paired HCC and adjacent non-tumorous liver tissues by real-time reverse transcription polymerase chain reaction (RT-PCR) analysis.

Results

Among these 114 miRNA, 31 miRNA were differentially expressed between HCC and non-cancerous liver tissues with 12 miRNA upregulated and 19 miRNA downregulated in HCC. The downexpression levels of miR-338 cases were found to be significantly associated with vascular invasion, intrahepatic metastasis, tumor size and tumor grade. However, there was no significant difference between miR-338 expression and other clinicopathological parameters in HCC. miR-338 was chosen for expression analysis by real-time RT-PCR analysis in an additional independent set of 36 pairs of HCC and NT. The results showed that the mRNA expression level of miR-338 in HCC was lower than in NT (P < 0.01), the mRNA expression level of miR-338 in M was lower than in NM (P < 0.01) and decreased miR-338 expression was correlated with increasing stage of HCC (P < 0.01).

Conclusion

Our study suggests that miR-338 expression could have relevance to the clinical behavior of HCC.

Key words: Hepatocellular carcinoma, MicroRNA, miR-338, Metastasis

Xiao-hui HUANG, Lian-zhou CHEN, Qiao SU, Ya-nan YAO, Long-juan ZHAN, Wen LI, Jiong BI, Wen-tao ZENG, Qian WANG. Expression and significance of miR-338 in hepatocellular carcinoma tissue samples[J]. Chinese Archives of General Surgery(Electronic Edition), 2011, 05(06): 465-470.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhptwkxwx.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-0793.2011.06.003

https://zhptwkxwx.cma-cmc.com.cn/EN/Y2011/V05/I06/465

Figures/Tables 3

References 13

1	Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res, 2006,66(15):7390-7394.
2	Calin GA, Liu CG, Sevignani C, et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci USA, 2004,101(32):11755-11760.
3	Peck D, Crawford ED, Ross KN, et al. A method for high-throughput gene expression signature analysis. Genome Biol, 2006,7(7):R61.
4	Murakami Y, Yasuda T, Saigo K, et al. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 2006,25(17):2537-2545.
5	Gramantieri L, Ferracin M, Fornari F, et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res, 2007,67(13):6092-6099.
6	Kutay H, Bai S, Datta J, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 2006,99(3):671-678.
7	Michael MZ, O’Connor SM, van Holst Pellekaan NG, et al. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res, 2003,1(12):882-891.
8	Cimmino A, Calin GA, Fabbri M, et al. CM. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA, 2005,102 (39):13944-13949.
9	Cummins JM, He Y, Leary RJ, et al. The colorectal micro RNAome. Proc Natl Acad Sci USA, 2006,103(10):3687-3692.
10	Gaur A, Jewell DA, Liang Y, et al. Characterization of micro RNA expression levels and their biological correlates in human cancer cell lines. Cancer Res, 2007,67(6):2456-2468.
11	Wong TS, Liu XB, Wong BY, et al. Mature miR-184 as potential oncogenic microRNA of squamous cell carcinoma of tongue. Clin Cancer Res, 2008,14(9):2588-2592.
12	Ma L, Teruya-Feldsteinet J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature, 2007,449(7163):682-688.
13	Tavazoie SF, Alarcónet C, Oskarsson T, et al. Endogenous human microRNAs that suppress breast cancer metastasis. Nature, 2008,451(7175):147-152.

miRNA名称	定位	P	肝癌组织中的表达强度	肝癌癌旁组织中的表达强度	在肝癌组织中表达上调/下调
let-7a	11q24.1	< 0.001	0.838 ± 0.154	1.510 ± 0.394	下调
miR-122a	18q21.31	< 0.00l	0.781 ± 0.116	1.507 ± 0.491	下调
miR-124a	8q12.3	< 0.001	0.984 ± 0.322	1.612 ± 0.261	下调
miR-125a	19q13.33	< 0.001	0.895 ± 0.295	1.544 ± 0.178	下调
miR-125b	21q21.1	< 0.001	0.718 ± 0.228	1.498 ± 0.488	下调
miR-126	9q34.3	< 0.001	0.741 ± 0.174	1.436 ± 0.244	下调
miR-126^*	9q34.3	< 0.001	0.729 ± 0.233	1.159 ± 0.365	下调
miR-129	7q32.1	< 0.001	0.864 ± 0.489	1.534 ± 0.367	下调
miR-143	5q32	< 0.001	0.769 ± 0.249	1.481 ± 0.439	下调
miR-145	5q32	< 0.001	0.630 ± 0.211	1.491 ± 0.278	下调
miR-152	17p13.1	< 0.001	0.713 ± 0.258	1.493 ± 0.300	下调
miR-15a	13q14.2	< 0.001	0.904 ± 0.328	1.595 ± 0.317	下调
miR-185	22q11.21	< 0.001	0.810 ± 0.320	1.234 ± 0.627	下调
miR-194	1q41	< 0.00l	0.604 ± 0.346	1.463 ± 0.426	下调
miR-195	19p13.12	< 0.001	0.910 ± 0.215	1.557 ± 0.458	下调
miR-199a	19p.32.2	< 0.001	0.869 ± 0.302	1.289 ± 0.478	下调
miR-200a	p36.33	< 0.001	0.919 ± 0.289	1.345 ± 0.339	下调
miR-27a	19p.32.2	< 0.001	0.769 ± 0.195	1.163 ± 0.248	下调
miR-338	17q25.3	< 0.001	0.743 ± 0.149	1.401 ± 0.273	下调
miR-107	10q23.31	< 0.001	1.633 ± 0.283	1.017 ± 0.257	上调
miR-128b	P22.3	< 0.001	1.629 ± 0.361	1.014 ± 0.248	上调
miR-130a	11q12.1	< 0.001	1.789 ± 0.348	0.649 ± 0.187	上调
miR-16	13q14.2	< 0.001	1.326 ± 0.239	1.020 ± 0.202	上调
miR-17-5p	13q31.3	< 0.001	1.514 ± 0.372	1.022 ± 0.184	上调
miR-205	1q32.2	< 0.001	1.511 ± 0.213	1.008 ± 0.182	上调
miR-207	9p21.1	< 0.001	1.444 ± 0.262	1.016 ± 0.231	上调
miR-221	Xp11.3	< 0.001	1.681 ± 0.358	1.001 ± 0.245	上调
miR-222	Xp11.3	< 0.001	1.513 ± 0.312	0.949 ± 0.199	上调
miR-224	Xq28	< 0.001	1，756 ± 0.396	0.969 ± 0，228	上调
miR-24	19p13.1	< 0.001	1.458 ± 0.211	1.001 ± 0.214	上调
miR-25	7q22.1	< 0.001	1.614 ± 0.212	0.955 ± 0.158	上调

miRNA名称	定位	P	肝癌组织中的表达强度	肝癌癌旁组织中的表达强度	在肝癌组织中表达上调/下调
let-7a	11q24.1	< 0.001	0.838 ± 0.154	1.510 ± 0.394	下调
miR-122a	18q21.31	< 0.00l	0.781 ± 0.116	1.507 ± 0.491	下调
miR-124a	8q12.3	< 0.001	0.984 ± 0.322	1.612 ± 0.261	下调
miR-125a	19q13.33	< 0.001	0.895 ± 0.295	1.544 ± 0.178	下调
miR-125b	21q21.1	< 0.001	0.718 ± 0.228	1.498 ± 0.488	下调
miR-126	9q34.3	< 0.001	0.741 ± 0.174	1.436 ± 0.244	下调
miR-126^*	9q34.3	< 0.001	0.729 ± 0.233	1.159 ± 0.365	下调
miR-129	7q32.1	< 0.001	0.864 ± 0.489	1.534 ± 0.367	下调
miR-143	5q32	< 0.001	0.769 ± 0.249	1.481 ± 0.439	下调
miR-145	5q32	< 0.001	0.630 ± 0.211	1.491 ± 0.278	下调
miR-152	17p13.1	< 0.001	0.713 ± 0.258	1.493 ± 0.300	下调
miR-15a	13q14.2	< 0.001	0.904 ± 0.328	1.595 ± 0.317	下调
miR-185	22q11.21	< 0.001	0.810 ± 0.320	1.234 ± 0.627	下调
miR-194	1q41	< 0.00l	0.604 ± 0.346	1.463 ± 0.426	下调
miR-195	19p13.12	< 0.001	0.910 ± 0.215	1.557 ± 0.458	下调
miR-199a	19p.32.2	< 0.001	0.869 ± 0.302	1.289 ± 0.478	下调
miR-200a	p36.33	< 0.001	0.919 ± 0.289	1.345 ± 0.339	下调
miR-27a	19p.32.2	< 0.001	0.769 ± 0.195	1.163 ± 0.248	下调
miR-338	17q25.3	< 0.001	0.743 ± 0.149	1.401 ± 0.273	下调
miR-107	10q23.31	< 0.001	1.633 ± 0.283	1.017 ± 0.257	上调
miR-128b	P22.3	< 0.001	1.629 ± 0.361	1.014 ± 0.248	上调
miR-130a	11q12.1	< 0.001	1.789 ± 0.348	0.649 ± 0.187	上调
miR-16	13q14.2	< 0.001	1.326 ± 0.239	1.020 ± 0.202	上调
miR-17-5p	13q31.3	< 0.001	1.514 ± 0.372	1.022 ± 0.184	上调
miR-205	1q32.2	< 0.001	1.511 ± 0.213	1.008 ± 0.182	上调
miR-207	9p21.1	< 0.001	1.444 ± 0.262	1.016 ± 0.231	上调
miR-221	Xp11.3	< 0.001	1.681 ± 0.358	1.001 ± 0.245	上调
miR-222	Xp11.3	< 0.001	1.513 ± 0.312	0.949 ± 0.199	上调
miR-224	Xq28	< 0.001	1，756 ± 0.396	0.969 ± 0，228	上调
miR-24	19p13.1	< 0.001	1.458 ± 0.211	1.001 ± 0.214	上调
miR-25	7q22.1	< 0.001	1.614 ± 0.212	0.955 ± 0.158	上调

临床病理参数		例数	miR-338表达强度	P值
年龄（岁）		?	?	0.613
?	< 50	6	1.879 ± 0.198	?
?	≥ 50	14	1.821 ± 0.224	?
性别		?	?	0.706
?	男	17	1.927 ± 0.443	?
?	女	3	2.051 ± 0.87l	?
饮酒史		?	?	0.851
?	无	16	1.789 ± 0.602	?
?	有	4	1.754 ± 0.228	?
病毒感染		?	?	0.467
?	无	2	2.149 ± 0.227	?
?	乙肝病毒	14	1.927 ± 0.444	?
?	丙肝病毒	4	1.691 ± 0.483	?
肝硬化		?	?	0.131
?	无	8	1.842 ± 0.281	?
?	有	12	1.628 ± 0.307	?
肿瘤大小（cm）		?	?	< 0.001
?	≤5	9	2.291 ± 0.304	?
?	> 5	11	1.727 ± 0.107	?
血清AFP（pg/L）		?	?	0.398
?	≤ 20	5	1.826 ± 0.254	?
?	> 20	15	1.739 ± 0.174	?
肿瘤分化程度		?	?	< 0.001
?	分化良	3	2.579 ± 1.041	?
?	中度分化	12	1.764 ± 0.338	?
?	未分化	5	1.239 ± 0.05l	?
TNM分级		?	?	< 0.001
?	Ⅰ	5	2.365 ± 0.336	?
?	Ⅱ	11	1.737 ± 0.246	?
?	Ⅲ	4	1.244 ± 0.344	?
血管侵犯		?	?	0.005
?	无	13	2.339 ± 0.614	?
?	有	7	1.529 ± 0.323	?
肝内转移		?	?	< 0.001
?	无	14	2.638 ± 0.248	?
?	有	6	1.681 ± 0.209	?

临床病理参数		例数	miR-338表达强度	P值
年龄（岁）		?	?	0.613
?	< 50	6	1.879 ± 0.198	?
?	≥ 50	14	1.821 ± 0.224	?
性别		?	?	0.706
?	男	17	1.927 ± 0.443	?
?	女	3	2.051 ± 0.87l	?
饮酒史		?	?	0.851
?	无	16	1.789 ± 0.602	?
?	有	4	1.754 ± 0.228	?
病毒感染		?	?	0.467
?	无	2	2.149 ± 0.227	?
?	乙肝病毒	14	1.927 ± 0.444	?
?	丙肝病毒	4	1.691 ± 0.483	?
肝硬化		?	?	0.131
?	无	8	1.842 ± 0.281	?
?	有	12	1.628 ± 0.307	?
肿瘤大小（cm）		?	?	< 0.001
?	≤5	9	2.291 ± 0.304	?
?	> 5	11	1.727 ± 0.107	?
血清AFP（pg/L）		?	?	0.398
?	≤ 20	5	1.826 ± 0.254	?
?	> 20	15	1.739 ± 0.174	?
肿瘤分化程度		?	?	< 0.001
?	分化良	3	2.579 ± 1.041	?
?	中度分化	12	1.764 ± 0.338	?
?	未分化	5	1.239 ± 0.05l	?
TNM分级		?	?	< 0.001
?	Ⅰ	5	2.365 ± 0.336	?
?	Ⅱ	11	1.737 ± 0.246	?
?	Ⅲ	4	1.244 ± 0.344	?
血管侵犯		?	?	0.005
?	无	13	2.339 ± 0.614	?
?	有	7	1.529 ± 0.323	?
肝内转移		?	?	< 0.001
?	无	14	2.638 ± 0.248	?
?	有	6	1.681 ± 0.209	?

[1]	Xuebing Shi, Yingdong Xie, Ni Xie, Chaoli Xu, Bin Yang, Guo Sun. Acoustic radiation force imaging for evaluating efficacy of radiotherapy in unresectable hepatocellular carcinoma patients with portal vein tumor thrombus [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2024, 21(08): 778-784.
[2]	Wei Liu, Yunfeng Niu, Jie An. LINC01232 promotes malignant progression of triple negative breast cancer through miR-516a-5p/BCL9 axis [J]. Chinese Journal of Breast Disease(Electronic Edition), 2024, 18(06): 330-338.
[3]	Shizhen Zhou, Xingya Zhu, Qinggang Yuan, Lixiang Liu, Kai Wang, Ji Miao, Chao Ding, Hao Wang, Wenxian Guan. Effect analysis of indocyanine green fluorescence imaging technique in laparoscopic lateral lymph node dissection of rectal cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2025, 19(01): 44-47.
[4]	Bin He, Jinfeng Ma. Risk factors for splenic hilar lymph node metastasis in gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(06): 694-699.
[5]	Jing Han, Shaolong Hao, Hua Kang. Retrospective analysis of clinical features of single-center thyroid carcinoma patients in Beijing [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 490-493.
[6]	Senyan Hu, Dong Xu, Jian Fang, Dongdong Xie, Caiqing Wang. Clinical study of laparoscopic anatomic hepatectomy by laennec membrane approach with ICG fluorescence imaging [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 513-516.
[7]	Jinhong Gao, Yumei Chen, Yun Guo. Application effect analysis of psychological counseling based on King interactive reaching theory in patients undergoing laparoscopic hepatocellular carcinoma resection [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 517-520.
[8]	Yibo Huang, Zhiyan Li, Chen Lin, Liang Tao, Meng Wang, Wenxian Guan. Research progress of lymph node tracer during radical gastrectomy of gastric cancer [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(05): 586-588.
[9]	Yi Lin, Wenlong Zhong, Kaiwen Li, Wang He, Tianxin Lin. Multidisciplinary consultation on difficult cases in Guangdong Urological Association （Phase 15）: comprehensive treatment of metastatic bladder cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 648-652.
[10]	Jingming Lu, Dawei Han, Yaoxing Ren, Tianxiao Huang, Junxi Xiang, Xufeng Zhang, Yi Lyu, Fumin Wang. Meta-analysis of lymph node metastasis prediction of intrahepatic cholangiocarcinoma based on preoperative radiomics [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 852-858.
[11]	Runjin Zhang, Pan Yang, Yansi Lin, Zunlong Liu, Jianping Liu, Xiaoyan Jin. Epstein-Barr virus-associated cholangiocarcinoma complicated with multiple metastases: a case report and Chinese literature review [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2024, 13(06): 865-869.
[12]	Weiwei Zhang, Qi Chen, Heyu Weng, Liang Huang. Preliminary study on prediction of lymph node metastasis of T1 colorectal cancer by random forest model [J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2024, 13(05): 389-393.
[13]	Yu Liu, Shaobin Duan, Zhixiang Ding, Zhitao Shi. Expression of miR-34a-5p in colon cancer patients and its correlation with clinical characteristics and prognosis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 485-490.
[14]	Guoqiang Wang, Gang Zhang, Jianpo Tang, Yuguo Zhang, Yongjiang Yang. Effects of LINC00839 on proliferation，apoptosis，and migration of colorectal cancer cells by regulating the miR-17-5p/WEE1 axis [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2024, 14(06): 491-499.
[15]	Ziyang Wang, Hongbin Wang, Xiaojing Liu. Progress in research of serum markers for diagnosis of alpha-fetoprotein negative hepatocellular carcinoma [J]. Chinese Journal of Clinicians(Electronic Edition), 2024, 18(07): 677-681.

Please choose a citation manager

Content to export